Minimal Ablation and Cellular Immune Therapy of Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Low-Grade Non-Hodgkin's Lymphoma, and Mantle Cell Lymphoma With Allogeneic Donor Stem Cells.

Trial Profile

Minimal Ablation and Cellular Immune Therapy of Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Low-Grade Non-Hodgkin's Lymphoma, and Mantle Cell Lymphoma With Allogeneic Donor Stem Cells.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2016

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Filgrastim
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; T cell prolymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Apr 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 04 Apr 2011 Planned end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Actual initiation date (Feb 2001) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top